Agenus Inc (AGEN) Return on Assets ROA from the second quarter of 2026 to second quarter of 2025 and for the year 2026, Average High and Low, Fundamental Ratios from Jun 30 2026 to Jun 30 2025 - CSIMarket
CSIMarket Company Name, Ticker, Industry, else..
 


• ROA Quarterly
• ROI Quarterly
• ROE Quarterly
Agenus Inc  (NASDAQ: AGEN)


Agenus Inc's ROA from the second quarter of 2026 to the second quarter of 2025 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics


What is Agenus Inc's ROA in the second quarter of 2026?
Agenus Inc achieved a return on average assets (ROA) of 44.76 % in its second quarter of 2026, this is above AGEN's average return on assets of -61.97%.
Agenus Inc assets over the 12 months ending in its second quarter of 2026 are valued at $205 million

Despite the company's net income deteriorating, Agenus Inc was able to improve its ROA compared to the first quarter of 2026.

However, within the Healthcare sector 23 other companies had a higher return on assets. While Return on assets, overall ranking has advanced in the Jun 30 2026 quarter, so far to 127, from total ROA ranking in the first quarter of 2026 at 3137.

What is ROA?


Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

Return On Assets (Jun 30 2026)
II. Quarter		 (Mar 31 2026)
I. Quarter		 (Dec 31 2025)
IV. Quarter		 (Sep 30 2025)
III. Quarter		 (Jun 30 2025)
II. Quarter
Y / Y Total Assets Change -6.76 % -6.87 % 0.23 % -1.19 % -36.66 %
Y / Y Net Income Change - - - - -
Net Income (TTM) in million 92 62 -3 -39 -170
Return On Assets (TTM) 44.76 % 29.97 % -1.45 % -18.54 % -80.17 %
AGEN's Total Ranking # 127 # 3137 # 3513 # 4348 # 4422
Total Assets (TTM) in million 173 186 227 236 185
Seq. Total Assets Change -7.38 % -17.79 % -3.75 % 27.22 % -7.48 %
Seq. Net Income Change - - - - -

AGEN's 5 Years Annual ROA >> Back to AGEN Management Effectiveness >> Compare AGEN ROA to its Competitors


Return On Assets Company Ranking
Within: No.
Industry # 6
Sector # 24
Overall # 78

Return On Assets Statistics
High Average Low
44.86 %
-61.97 %
-122.38 %
(Jun 30 2026)   (Dec 31 2018)



  News about Agenus Inc Return on Assets ROA

Agenus on the Rise Trailblazing Immunotherapy Innovations Set Stage for Breakthroughs in Cancer Treatment and Unprece...

Unlocking New Horizons in Cancer Treatment: Agenus’ Promising Advances in ImmunotherapyIn an era defined by groundbreaking medical innovations, Agenus Inc. a pioneering leader in immunological cancer therapy, is making significant strides toward transforming the landscape of cancer treatment. Recently, the company announced its participation in the Society for Immunotherapy of Cancer (SITC) 2024 Annual Meeting in Houston, Texas, an event highly anticipated by the medical community due to its unveiling of promising data on two of Agenus investigational immunotherapy candidates: botensilimab and AGEN1721. Breakthroughs in Immunotherapy: Botensilimab and AGEN1721Botensilimab and AGEN1721 stand at the forefront of Agenus innovative efforts to combat cancer. These experimental agents are designed to overcome one of oncology s most formidable challenges immune-resistant tumors. Dr. Dhan Chand, a key figure in Agenus research team, will present compelling data that may signal a new era in immunotherapy. The detailed presentations will provide intricate data analyses and real-world implications for these immune-modulating agents, showcasing their potential efficacy in eradicating hard-to-treat cancers.



Financial Statements
Agenus Inc's Assets $ 173 million AGEN's Balance sheet
Agenus Inc's Income $ -1 million Quarterly AGEN's Income Statement
AGEN's Income by Division See AGEN's Income by Division



Annual Return On Assets (Dec 31 2025)
FY 2025		 (Dec 31 2024)
FY 2024		 (Dec 31 2023)
FY 2023		 (Dec 31 2022)
FY 2022		 (Dec 31 2021)
FY 2021
Y / Y Total Assets Change 10.96 % -27.92 % -24.09 % -11.25 % 117.22 %
Total Assets in million 251 226 314 414 466
Y / Y Net Income Change - - - - -
Net Income in million -3 -232 -257 -231 -29
Annual Return On Assets -1.23 % -102.65 % -82.01 % -55.77 % -6.16 %

AGEN's 5 Years Annual ROA >> Back to AGEN Management Effectiveness >> Compare AGEN ROA to its Competitors



More Return On Assets Ratios
AGEN's' Return on Assets at Yahoo Finance
Biotechnology & Pharmaceuticals Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
AGEN's Roa Ratio versus Biotechnology & Pharmaceuticals Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for AGEN's Competitors
Subscribers only: Roa for Agenus Inc's Suppliers
Subscribers only: Return On Assets for AGEN's Customers

You may also want to know
AGEN's Roi AGEN's Inventory Turnover Ratio AGEN's Growth Rates AGEN's Dividend Comparisons
AGEN's Profitability Ratios AGEN's Asset Turnover Ratio AGEN's Dividend Growth
AGEN's Roe AGEN's Valuation Ratios AGEN's Financial Strength Ratios AGEN's Dividend Payout Ratio



Companies with similar Return On Assets at Jun 30 2026, within Healthcare Sector ROA
Elutia Inc   108.72 %
Silexion Therapeutics Corp  99.09 %
Arbutus Biopharma Corp  96.04 %
Pulmatrix Inc   94.81 %
Quince Therapeutics Inc   88.46 %
Interpace Biosciences Inc   85.91 %
Oncotelic Therapeutics Inc   81.75 %
Rigel Pharmaceuticals Inc  72.27 %
Actinium Pharmaceuticals Inc  71.73 %
Sanuwave Health Inc   71.60 %
Exelixis Inc   70.51 %
Rallybio Corporation  64.51 %
Oramed Pharmaceuticals Inc  64.18 %
Fortress Biotech Inc   60.88 %
Atlantic Coastal Acquisition Corp Ii  54.09 %
Lensar Inc   47.48 %
Elite Pharmaceuticals Inc   46.11 %
Omeros Corporation  46.05 %
Q32 Bio Inc   45.18 %
Aurinia Pharmaceuticals Inc   44.95 %
Agenus Inc  44.86 %
Earth Science Tech Inc   44.02 %
Liquidia Corporation  36.30 %
Ironwood Pharmaceuticals inc   34.34 %
Idexx Laboratories Inc  33.61 %
Tg Therapeutics Inc   33.59 %
Meiragtx Holdings Plc  29.37 %
Indivior Pharmaceuticals Inc   28.21 %
Qhslab Inc   27.12 %
Adma Biologics Inc   26.58 %

Date modified: 2026-09-26T07:00:32+00:00


Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.